A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies.

@article{Kohrt2013API,
  title={A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies.},
  author={H. Kohrt and J. Godwin and I. Lossos and M. Williams and J. Timmerman and B. Link and S. Goldberg and A. McGirr and J. Kurland and J. Wigginton and L. Cohen and R. Levy},
  journal={Journal of Clinical Oncology},
  year={2013},
  volume={31}
}
  • H. Kohrt, J. Godwin, +9 authors R. Levy
  • Published 2013
  • Medicine
  • Journal of Clinical Oncology
  • TPS3108 Background: CD137 (4-1BB) is a costimulatory molecule that belongs to the TNF superfamily. It is upregulated on activated lymphocytes, NK cells and dendritic cells and plays an important role in the potentiation of antigen-specific immune responses as well as in antibody-dependent cell-mediated cytotoxicity (ADCC). Urelumab is an agonistic antibody targeting the CD137 receptor. Preclinical evidence has shown that there is modulation of CD137 expression on NK cells after exposure to… CONTINUE READING
    11 Citations

    Topics from this paper

    Advances in the treatment of follicular lymphoma
    Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
    • 144
    • PDF
    Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches.
    • 28
    Renewed interest for low‐dose radiation therapy in follicular lymphomas: From biology to clinical applications
    • 2
    • Highly Influenced